is all in $AAPL $TSLA and $PMCB
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bavarian Nordic Declares Subscription Price And Number Of Shares To Be Issued To JJDC Under License And Collaboration Agreement
Bavarian Nordic A/S (CPH:BAVA)(OTC:BVNRY) on Wednesday announced the subscription price and the number of new shares to be issued to Johnson & Johnson Innovation - JJDC Inc (JJDC) in connection with the license and collaboration agreement entered into on 27 July 2017 with Janssen Pharmaceuticals Inc, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
According to the company, the subscription price is DKK405.1578 per share of DKK10 and has been calculated based on the simple average of the volume weighted average price of the company's shares on Nasdaq Copenhagen during a period of ten consecutive trading days starting on 27 July 2017 and ending on 9 August 2017.
Under the subscription agreement entered into on 27 July 2017 between JJDC and Bavarian Nordic, JJDC will subscribe for Bavarian Nordic shares for USD33,000,000, corresponding to DKK207,482,135.
Consequently, Bavarian Nordic will issue 512,102 new shares of DKK10 each (equal to approximately 1.63% of existing share capital of the company) at a price of DKK405.1578 per share.
These new shares will be issued upon closing of the transaction with Janssen which is awaiting clearance under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act.
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacturing and commercialisation of cancer immunotherapies and vaccines for infectious diseases, based on the company's live virus vaccine platform.
https://www.barchart.com/stocks/quotes/JNJ#/news/3740382/bavarian-nordic-declares-subscription-price-and-number-of-shares-to-be-issued-to-jjdc-under-license-and-collaboration-agreement
J&J has opened several biotech incubator sites, with one in Toronto opened in May of 2016.
http://jlabs.jnjinnovation.com/locations/jlabs-toronto
Remember when KW was in Toronto at the Fairmont?
Take a look at how close the Fairmont is to JLabs Canada:
https://www.google.com/maps/dir/Fairmont+Royal+York,+Front+Street+West,+Toronto,+ON,+Canada/JLABS+@+Toronto,+661+University+Avenue,+Suite+1300,+MaRS+Centre,+West+Tower,+Toronto,+ON+M5G0B7,+Canada/@43.6525296,-79.3936511,15z/data=!3m1!4b1!4m13!4m12!1m5!1m1!1s0x882b34d3152a8e61:0x154fe230e73270f!2m2!1d-79.3812245!2d43.6459574!1m5!1m1!1s0x882b34b7d77de623:0x9b960e67d67a9351!2m2!1d-79.389551!2d43.659446
Regarding Austrianova's FB post, J&J ended its partnership with Capricor in July. The partnership was announced in Jan of 2014.
http://www.fiercebiotech.com/biotech/capricor-yo-yos-as-j-j-dumps-stem-cell-partnership
For those of you who are wondering what sort of Kaboom! could happen please take a look at $CAPR's 5 year chart. $PMCB is no $CAPR, just pointing out to an example of what happened to a stock after a Janssen partnership was announced.
Overall, strongly reinforces my support for KW's comments about taking the time to get the IND absolutely perfect. Several other biotech stocks I own have taken hits recently over what I believe to be poorly designed trials of otherwise useful new drugs.
Go $PMCB!
The article that got me interested in $PMCB:
PharmaCyte Going Head to Head with Eli Lilly's Pancreatic Cancer Drug in New Clinical Trial
https://finance.yahoo.com/news/pharmacyte-going-head-head-eli-141000857.html
Thank you! As a $PMCB and $JNJ shareholder I'm very, very excited about this possibility!
Regarding Janssen and $PMCB speculation, take a look at this article on Janssen parent JNJ:
It takes an average of 12 years to get a new drug to market. This is a marathon, not a sprint.
Go $PMCB
"Zug, Switzerland, August 3, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will report its financial results for the second quarter of 2017 on Thursday, August 10, 2017. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time) to discuss the Company's financial results and to provide a general business update.
To participate in this conference call, dial 1-877-280-1254 (USA) or +1-212-444-0896 (International), and enter passcode 1366409. A live webcast of the conference call can be accessed on the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call."
I personally like it when companies do calls pre-market. When they pick after-market there is usually bad news. Pre-market, on a Thursday, looks good to me.
Also, wow, $EARS law firm is Davis Polk in NY. That is one major corporate law firm powerhouse. One of the oldest corporate law firms in the US.
I have a good feeling on $WARM as well. Loaded up and ready for Boom!
Property description from commercial real estate website:
Description
The WesTech/Meadows Business Park consists of twelve single story flex and mid-rise office buildings conveniently located directly off Rt. 29 in Silver Spring, Maryland. The park sits on 36 acres of well landscaped grounds, and boasts convenient access to Rt-495, I-95, Rt. 29, and the Intercounty Connector, Rt. 200. WesTech/Meadows offers NNN flex opportunities with office and loading dock capabilities combined in one workspace, as well as traditional office settings with onsite leasing, management, and engineering. The WesTech/Meadows Business Park is also easily accessible to the FDA headquarters at White Oak, the East County Center for Science & Technology, as well as the brand new Washington Adventist Hospital, expected to open in 2019. Amenities include an onsite Deli, and numerous restaurants and office services within a one mile radius. Parking is free and ample!
The WesTech/Meadows Business Park consists of twelve single story flex and mid-rise office buildings conveniently located directly off Rt. 29 in Silver Spring, Maryland. The park sits on 36 acres of well landscaped grounds, and boasts convenient access to Rt-495, I-95, Rt. 29, and the Intercounty Connector, Rt. 200.
http://www.loopnet.com/Listing/19060467/12510-Prosperity-Dr-Silver-Spring-MD/
Suite 302, next door to $PMCB is/was available:
302
Space Available: 2,437 SF
Rental Rate: $4,772.46 /Month
Lease Type: Full Service
Min. Divisible: 2,437 SF
Max. Contiguous: 2,437 SF
compare to smaller first floor space:
140
Space Available: 1,513 SF
Rental Rate: $2,962.96 /Month
Lease Type: Full Service
Min. Divisible: 1,513 SF
Max. Contiguous: 1,513 SF
http://www.cityfeet.com/Partner/ForLease/LN20083727/12510-Prosperity-Drive-Silver-Spring-MD-20904
OK, maybe because many people are fully loaded with $50K+ in stock. As Pete knows wells, the $PMCB float is locked up tight. The nonsense we see where 2 million shares are bought and the price doesn't move, then 10,000 are sold at it drops 3% only shake the weakest of hands. But it's as plain as day to see the MMs want people ready to sell shares during the next major leg up.
IF you think nada is happening before 2018 you are overlooking the three obvious catalysts that we could see dropped literally any day now:
Filing of IND for Phase 2b for pancreatic cancer.
Request pre IND meeting for diabetes.
Partnership with big pharma (my money is on Janssen).
Absolutely true. People with 10K shares, yeah, they want their limited funds growing yesterday. People with 500K+ shares, well, they see the light at the end of the tunnel growing brighter each day.
Yup, Johnson & Johnson management is waaaaay too cautious and conservative IMHO. So all the great synergies created by PMCB working with Janssen are sorta tempered by J&J's cautious culture.
KW's recent behaviour absolutely screams of NDAs to me too.
In the end, however, once J&J and their lawyers deem it's ok to go public with news we will see one heck of a jump. The resources and knowledge Janssen has are just incredible.
Interesting that none of the Chicken Littles have commented on these facts:
From last year, but just another reason to think Janssen and $PMCB will be working together soon:
http://money.cnn.com/news/newsfeeds/articles/marketwire/11G081846-001.htm
I missed that! Great catch!
Member mark for you!
well deserved bump
Annual report is out
488 block size is back.
I bought the bulk of my shares at .15. I believe in KW and $PMCB. I'm invested in many biotechs and I know how important trial design is.
KW wants to get the pancreatic cancer Phase 2b setup perfectly and I 100% agree with him. Expecting great news any week now. $PMCB wants to enroll first patient in trial in Q4, which means the IND has to be filed soon to give the FDA enough time to review and approval the trial.
Dr. Sher's hiring tells me $PMCB will have multiple irons in the fire very soon.
So I'm expecting very good news to drop in rapid fire in the coming weeks.
Letter to shareholders:
http://cooltechnologiesinc.com/letter-to-shareholders-july-2017/
$PMCB to be firing on all cylinders soon!
I'm fully loaded and ready for all the exciting catalysts coming our way.
Well, the markets are vastly different.
Antidiabetics Market size worth USD $116 Billion by 2023: Global Market Insights Inc.
https://globenewswire.com/news-release/2016/07/05/853712/0/en/Antidiabetics-Market-size-worth-USD-116-Billion-by-2023-Global-Market-Insights-Inc.html
Pancreatic Cancer Treatment Market Size Worth $4.2 Billion By 2025
http://www.grandviewresearch.com/press-release/global-pancreatic-cancer-treatment-market
Excellent, thanks!
Found a few of Dr. Linda Sher's Clinical Trials as well, also focusing on the liver.
https://clinicaltrials.gov/ct2/show/NCT02502019
https://clinicaltrials.gov/ct2/show/NCT01471028
Go $PMCB!
Thanks!
Looking into Dr. Linda Sher. She has an impressive body of work. Finding medical papers is tricky, looks like she appears as "Sher, L" and as "Sher, LS" sometimes.
Anyway, take a look:
https://www.ncbi.nlm.nih.gov/pubmed/?term=Sher+LS%5BAuthor%5D
Note her work regarding the liver. I do believe this is a huge clue as to what's next for $PMCB.
Diabetes pre-IND meeting request, anyone?
Very true. I see solid tumors are low hanging fruit so to speak, so it makes sense to me to see them focus there initially. Would absolutely go nuts to see cancer and diabetes being submitted back-to-back!
Can you imagine share price of $PMCB with multiple, carefully designed TD2 Phase 2b trials underway? Boom!
PhamaCyte has impressive Management:
http://pharmacyte.com/management/
Dr. Linda S. Sher - Chief Medical Officer shows us exactly where $PMCB is going! Multiple, simultaneous clinical trails! Boom!
To me this is just another indication that $PMCB will be partnering with Janssen. Dr. Sher has a very impressive resume and her experience overseeing 50-70 simultaneous clinical trials is a key piece of information here.
Janssen has a huge product line in Oncology: http://www.janssen.com/products/Oncology
Someone like Dr. Sher would be perfect for managing simultaneous trials of CiaB and the various Janssen medicines for solid tumors.
I know we are all waiting for the IND to be filed. But news like our new CMO Dr. Sher and our new Board member Dr. Abecassis are very strategic and telegraph important information to savvy investors.
Why a new Board member? Maybe because something like a partnership agreement with Janssen required the vote of a full Board of six members. Why a new CMO with an impressive background of being the Principal or Co-Principal Investigator for more than 50 clinical trials? Maybe because CiaB could be used with dozens of different medicines to treat solid tumors. Think about it. Did Dr Sher really leave her post at USC Keck's School of Medicine to join $PMCB to do ONE clinical trial?
See my post from Sunday
What legal problems?
He's in Canada. He says Canadians will outnumber American employees soon.
How else can that be interpreted?
Thanks, and exactly right. A lawyer uses terms like "majority interest" or "controlling interest" to state the percentage of ownership of a company.
Pointing out that you are going from 10 employees to 21 is a very subtle way to convey a tremendous amount of information. You have to read between the lines.
PMCB is chugging along fine with the upcoming Phase 2b trial. An influx of 11 new Canadian workers means, to me, the diabetes program is being taken off the back burner.
Exciting times to be a $PMCB shareholder!
PMCB has 10 employees (as of Feb 6, 2017).
KM says on FB that PMCB will soon have more Canadian than American employees.
To me that means at least 11 new Canadian employees.
I think KW signed partnership papers and his hands are now tied because of a NDA.
He's a lawyer. Comments like "soon there will be more Canadians", when run through Google's Legalease Translator, mean a Canadian company has taken a controlling interest in $PMCB. Last time I checked, PMCB had ten employees. Now it will pop to 21 with 11 new Canadians. Let that sink in.
Evidence 1: PMCB has grown to at least 21 employees, with at least 11 being Canadian.
Evidence 2: KW's FB friends were offering congratulations.
Evidence 3: KW's FB profile is now private, i.e., he was told to make his FB profile private.
You can take all of this anyway you want, but I'm seeing actions and reactions here and to me it smells like Janssen is about to announce some great news.
As a $JNJ shareholder and a $PMCB shareholder, I couldn't be happier! It's the beginning of a great partnership that will benefit those who have have cancer and those who have diabetes!
$3 a share? You have to think how much money KW would want to walk away into a blissful mixology sunset!
repost from last night:
OK, we have the Imperial Room at the Fairmont Royal York Hotel in Toronto Canada. Which Canadian pharma companies are in Toronto?
How about Johnson & Johnson's Janssen (19 Green Belt Dr, Toronto, ON M3C 1L9, Canada). It's a 19 minute drive from the Fairmont to Janssen.
https://www.google.com/maps/dir/Fairmont+Royal+York,+Front+Street+West,+Toronto,+ON,+Canada/Janssen+Inc,+Toronto,+ON,+Canada/@43.6852292,-79.4370035,12z/data=!3m1!4b1!4m13!4m12!1m5!1m1!1s0x882b34d3152a8e61:0x154fe230e73270f!2m2!1d-79.3812245!2d43.6459574!1m5!1m1!1s0x89d4cd0b175c9cfd:0x16f6ca9e2aefa560!2m2!1d-79.3382139!2d43.7286224
Why would that be a good fit? Because Janssen has a suite of over nearly 30 oncology drugs.
http://www.janssen.com/products/Oncology
How many of those drugs would get renewed exclusivity if incorporate with $PMCB's cell-in-a-box technology?
Any other reasons such a partnership would be a good fit for $PMCB? How about Johnson & Johnson's Diabetes Institute.
https://www.jjdi.com/about-us
Wow. Pure speculation on my part, but one can dream!
OK, we have the Imperial Room at the Fairmont Royal York Hotel in Toronto Canada. Which Canadian pharma companies are in Toronto?
How about Johnson & Johnson's Janssen (19 Green Belt Dr, Toronto, ON M3C 1L9, Canada). It's a 19 minute drive from the Fairmont to Janssen.
https://www.google.com/maps/dir/Fairmont+Royal+York,+Front+Street+West,+Toronto,+ON,+Canada/Janssen+Inc,+Toronto,+ON,+Canada/@43.6852292,-79.4370035,12z/data=!3m1!4b1!4m13!4m12!1m5!1m1!1s0x882b34d3152a8e61:0x154fe230e73270f!2m2!1d-79.3812245!2d43.6459574!1m5!1m1!1s0x89d4cd0b175c9cfd:0x16f6ca9e2aefa560!2m2!1d-79.3382139!2d43.7286224
Why would that be a good fit? Because Janssen has a suite of over nearly 30 oncology drugs.
http://www.janssen.com/products/Oncology
How many of those drugs would get renewed exclusivity if incorporate with $PMCB's cell-in-a-box technology?
Any other reasons such a partnership would be a good fit for $PMCB? How about Johnson & Johnson's Diabetes Institute.
https://www.jjdi.com/about-us
Wow. Pure speculation on my part, but one can dream!
$BLDV is a very well diversified play in the cannabis space. I'm holding out for cooper here.